ShangPharma Corporation, Special/Extraordinary Shareholders Meeting, Mar 20, 2013., at 10:00 China Standard Time. Location: 42nd Floor, Edinburgh Tower. Agenda: To consider on the proposal to authorize and approve the previously announced agreement and plan of merger, dated December 21, 2012, among the company, ShangPharma Holdings Limited, ShangPharma Parent Limited and ShangPharma Merger Sub Limited.

ShangPharma Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2012. For the quarter, the company reported net revenues of $31.9 million, an increase of 10.6% from $28.8 million in the third quarter of 2011. Higher volumes from the company's top customers and greater cross-selling of services were major drivers of this growth. Net revenues this quarter were partially impacted by a deferral in revenue of certain integrated services projects. Profit from operations was $1.2 million, a decrease of 41.6% from $2.1 million in the third quarter of 2011, primarily due to facility expansion costs, higher labor costs as a percentage of total net revenues resulting from an increase in the number of scientific research staff members, including senior scientists, during the first half of 2012, and higher listed company-related professional fees. These factors were partially offset by an increase in net revenues and cost savings from the aforementioned VAT reform. Non-GAAP profit from operations was $2.4 million, a decrease of 37.0% from $3.9 million in the third quarter of 2011. This was due to the reasons mentioned in the above discussion of GAAP profit from operations, excluding the impact of share-based compensation expenses. Net income decreased by 39.5% year over year to $1.6 million, primarily due to lower profit from operations and lowers other income, including a smaller foreign exchange gain, an increased foreign exchange forward contract gain and lower interest income. Diluted earnings per ADS were $0.08, which compares with $0.14 in the third quarter of 2011. Non-GAAP net income was $2.8 million, a decrease of 36.3% from $4.4 million in the third quarter of 2011. This was primarily due to the reasons mentioned in the above discussion of GAAP net income. Non-GAAP diluted earnings per ADS was $0.15, which compares with $0.24 in the third quarter of 2011. During the quarter, capital expenditures totaled $5.0 million, primarily from purchase of equipment and investment in leasehold improvements of various facilities. Income from operations before income taxes was $2.93 million compared to 1.89 for the same period a year ago. For the nine months, the company reported revenue of $81.19 million compared to $94.46 million for the same period a year ago. Profit from operations was $7.37 million compared to $3.58 million for the same period a year ago. Income from operations before income taxes was $10.64 million compared to $3.59 million for the same period a year ago. Net income was $8.95 million compared to $3.71 million for the same period a year ago. Basic and diluted earnings per ADS was $0.48, which compares with $0.20 for the same period last year. Non-GAAP profit from operations was $11.89 million compared to $7.84 million for the same period a year ago. Non-GAAP net income was $13.48 million compared to $7.97 million for the same period a year ago. Non-GAAP net income per ADS, diluted was $0.48, which compares with $0.20 in the third quarter of 2011. The company revised its previously announced guidance for net revenues and capital expenditures for the full year 2012, and reconfirms its guidance for non-GAAP gross margin for the full year 2012. The Company expects: Net revenues to be approximately $125.0 million to $128.0 million, which represents growth of approximately 11.1% to 13.8% compared with the full year of 2011. Non-GAAP gross margin to be in the range of 30.0% to 31.5%. Capital expenditures to be approximately $19.0 million to $21.0 million. This reflects the company's current view and is subject to change.

ShangPharma Corporation, Annual General Meeting, Dec 12, 2012., at 10:00 China Standard Time. Location: 42nd Floor, Edinburgh Tower.